CJC-1295 Dosage: Complete Protocol Guide

The DAC modification attaches CJC-1295 to albumin in the bloodstream through a reactive chemical group. Albumin is a large protein with a half-life of approximately 20 days, and once CJC-1295 binds to it, the peptide inherits that slow clearance rate. The result: a single injection elevates GH levels for 5 to 8 days (Teichman et al., J Clin Endocrinol Metab 2006).

In the key human trial, a single 60 mcg/kg dose of CJC-1295-DAC increased mean GH levels 2 to 10-fold above baseline for up to 6 days. IGF-1 levels rose by 1.5 to 3-fold and remained elevated for 9 to 11 days after a single injection.

The tradeoff is specificity. Because DAC keeps CJC-1295 active for days, GH elevation is sustained rather than pulsatile. Your pituitary normally releases GH in sharp bursts, especially during deep sleep. DAC creates a constant, low-grade stimulus instead. Some researchers consider this less physiological than the pulsatile pattern. Others argue the sustained IGF-1 elevation is the primary therapeutic benefit regardless of the GH release pattern.

Without the DAC modification, CJC-1295 has a half-life of approximately 25 to 30 minutes. This is dramatically longer than natural GHRH (under 7 minutes) but far shorter than the DAC version. The result is a sharp, pulsatile GH release that peaks within 15 to 30 minutes and returns to baseline within 2 to 3 hours.

Modified GRF 1-29 (also sold as "CJC-1295 no DAC" or simply "Mod GRF") contains amino acid substitutions at positions 2, 8, 15, and 27 of the original GHRH(1-29) fragment. These substitutions protect against dipeptidyl peptidase-IV (DPP-IV) cleavage, the enzyme that destroys natural GHRH within minutes (Alba et al., J Med Chem 2006).

The short half-life is actually the advantage for many users. It produces GH release that mimics the body's natural pulsatile rhythm. When injected before bed, it amplifies the largest natural GH surge of the day (the one that occurs during slow-wave sleep). This pulsatile pattern preserves the negative feedback loop: somatostatin still regulates the system normally between pulses.

The DAC version is dosed infrequently because of its long half-life. One injection sustains GH elevation for nearly a week.

In the Teichman et al. trial, subjects receiving weekly doses of 30 to 60 mcg/kg (roughly 2,000 to 4,000 mcg for an 80 kg adult) showed sustained IGF-1 elevation with no serious adverse events over the study period (Teichman et al., J Clin Endocrinol Metab 2006).

Most community protocols settle on 2,000 mcg once weekly, injected subcutaneously. Some users prefer splitting to 1,000 mcg twice weekly (e.g., Monday and Thursday) for more stable blood levels. Both approaches produce comparable IGF-1 elevation.

CJC-1295 with DAC is typically used standalone, without ipamorelin. The sustained GH elevation from DAC already provides continuous stimulation. Adding a GHRP on top of that can lead to excessive GH exposure and increased side effects like water retention and numbness.

Without DAC, the peptide clears within hours. Daily (or multiple daily) injections are required.

The saturation dose for Mod GRF 1-29 is approximately 100 mcg (or 1 mcg/kg body weight). Above this threshold, the pituitary's GHRH receptors are fully occupied, and additional CJC-1295 produces diminishing returns. Going from 100 mcg to 300 mcg does not triple GH output. It may increase it by 20 to 30% at best (Ionescu & Ghigo, Endocrine 2005).

This is why stacking with ipamorelin is standard practice. Rather than increasing CJC-1295 above its saturation dose, adding a second peptide that activates a completely different receptor (the ghrelin/GHS receptor) amplifies total GH release more efficiently. The two peptides work through separate pathways and produce a synergistic pulse.

Growth hormone declines approximately 14% per decade after age 30. By age 60, many adults produce less than half the GH they did at 25. This decline contributes to thinner skin, reduced bone density, increased visceral fat, and slower recovery from injury (Rudman et al., N Engl J Med 1990).

The anti-aging protocol aims to restore GH levels toward youthful ranges without pushing into supraphysiological territory. Conservative dosing is the priority. More is not better when the goal is longevity.

The before-bed timing amplifies the natural nocturnal GH surge, the largest pulse of the day. This protocol produces the most physiological GH pattern: a strong nighttime burst followed by daytime clearance. IGF-1 typically rises 30 to 50% above baseline on this regimen, placing most users in the upper quartile of their age-adjusted reference range. For peptides that target other aspects of aging, see our GHK-Cu injection dosage guide.

Growth hormone is a powerful lipolytic hormone. It mobilizes fatty acids from adipose tissue, particularly visceral fat, and shifts metabolism toward fat oxidation. Elevating GH through CJC-1295 and ipamorelin increases resting energy expenditure and preferentially targets the deep abdominal fat that wraps around organs (Møller & Jørgensen, Endocr Rev 2009).

The fat loss protocol adds a fasted morning injection to the standard before-bed dose. GH mobilizes fatty acids; the fasted state prevents insulin from re-storing them.

The morning injection on an empty stomach is critical. Insulin opposes GH-mediated lipolysis. Eating before or immediately after the injection blunts the fat-burning cascade. Wait at least 20 to 30 minutes after injection before eating. Light fasted cardio during that window oxidizes the mobilized fatty acids. See our tesamorelin dosage for fat loss guide for how CJC-1295 compares to FDA-approved GH-releasing peptides for visceral fat.

GH does not build muscle the way testosterone does. It does not directly activate the androgen receptor. Instead, GH acts indirectly through IGF-1 to stimulate protein synthesis, promote satellite cell proliferation, and accelerate recovery between training sessions (Velloso, Br J Pharmacol 2008).

The practical benefit for athletes and lifters: faster recovery, better sleep quality, and improved body composition over months of consistent use. The muscle growth protocol maximizes daily GH exposure through three injection windows.

The post-workout window takes advantage of the exercise-induced GH surge. Resistance training itself stimulates GH release; adding CJC-1295 and ipamorelin within 30 minutes of finishing amplifies that response. Wait to eat your post-workout meal until 20 to 30 minutes after the injection.

This three-times-daily schedule demands commitment. For those who find it impractical, two daily injections (morning and night) capture roughly 80% of the benefit. For broader muscle-building peptide strategies, see our peptides for bodybuilding guide and peptide stacking guide.

Growth hormone and sleep exist in a bidirectional relationship. Deep sleep triggers GH release, and GH itself promotes the transition into slow-wave sleep stages. Users consistently report that GH peptides are among the most noticeable sleep-quality interventions they have tried.

The sleep protocol is the simplest. One injection, one time of day, low dose.

A small study of 8 healthy older adults found that GHRH administration before sleep increased slow-wave sleep duration by 25% and decreased REM sleep latency (Steiger et al., Neuroendocrinology 1992). The effect was most pronounced during the first half of the night, when endogenous GH secretion is naturally highest.

Inject on an empty stomach. A meal within the preceding 2 hours raises insulin and blunts GH release. Many users combine this with magnesium glycinate (400 mg) and glycine (3 g) for additive sleep support, though no trial has tested this specific combination with GH peptides.

Minimum protocol: Once daily (before bed), 100 mcg CJC + 200 mcg ipamorelin.

Maximum protocol: Three times daily, 100-200 mcg CJC + 200-300 mcg ipamorelin per injection.

Both peptides can be drawn into the same syringe and injected together. They are chemically compatible and do not degrade each other in solution. Draw the CJC-1295 first, then the ipamorelin, from separate vials. Some compounding pharmacies sell pre-mixed CJC-1295/ipamorelin vials, which simplifies the process to a single draw.

Cycle length: 8 to 16 weeks on, followed by 4 to 8 weeks off. The off period prevents GHRH receptor desensitization and allows the pituitary to reset. Users who run continuous cycles without breaks often report diminishing returns after 4 to 5 months.

Use the CJC-1295 + Ipamorelin dosage calculator to determine your exact injection volume based on vial concentration. Check your stack for interactions with the peptide interaction checker.

Four GHRPs are commonly available: ipamorelin, GHRP-2, GHRP-6, and hexarelin. Each activates the GHS receptor, but their side effect profiles differ substantially.

GHRP-6 causes intense hunger within 20 minutes of injection. For someone in a caloric deficit targeting fat loss, that hunger response undermines the entire protocol. GHRP-2 is a reasonable middle ground: stronger GH release than ipamorelin, moderate side effects. Hexarelin produces the largest GH pulse but desensitizes the GHS receptor within 4 to 8 weeks, making it unsuitable for long cycles (Rahim et al., Clin Endocrinol 1998).

Ipamorelin is the default choice because it works well enough, long enough, with the fewest disruptions to cortisol, prolactin, and appetite.

A user reads "CJC-1295 dose: 2,000 mcg" from a DAC protocol and injects 2,000 mcg of Mod GRF 1-29 three times daily. That is 6,000 mcg per day of a peptide that saturates receptors at 100 mcg. The excess floods the pituitary with GHRH signal, leading to receptor desensitization within days rather than months.

The result: severe water retention, numbness and tingling in the hands (carpal tunnel symptoms from excessive GH), facial flushing, and paradoxically reduced GH output as the pituitary downregulates its response. After 2 to 3 weeks, the user notices the peptide "stopped working." It did not stop working. The receptors stopped responding because they were overwhelmed.

The fix: verify which variant you have before your first injection. CJC-1295 with DAC is dosed in milligrams (1-2 mg) once or twice weekly. CJC-1295 without DAC is dosed in micrograms (100-300 mcg) one to three times daily. If your vendor label says "CJC-1295" without specifying DAC, assume it is the no-DAC version (Mod GRF 1-29) unless confirmed otherwise. The no-DAC version is far more commonly sold.

A user injects 100 mcg CJC-1295 plus 200 mcg ipamorelin 20 minutes after a carbohydrate-heavy dinner. Blood glucose is elevated. Insulin is elevated. The pituitary receives the GHRH signal but the downstream GH response is blunted by 60 to 80%.

This is not a theoretical concern. Insulin is one of the strongest inhibitors of GH secretion. A study in healthy adults showed that oral glucose loading reduced GH response to GHRH by 75% compared to fasted conditions (Giustina & Veldhuis, Endocr Rev 1998). Eating before injection does not make CJC-1295 dangerous. It makes it ineffective. You are paying for a peptide and then blocking its mechanism with food.

The fix: inject on an empty stomach. Fast for at least 2 hours before injection. After injection, wait 20 to 30 minutes before eating. The GH pulse peaks within 15 to 30 minutes of a no-DAC injection and clears within 2 hours. That fasting window is when the peptide does its work.

Always use bacteriostatic water for multi-dose vials. The benzyl alcohol preservative prevents bacterial growth and allows the reconstituted solution to last 28 to 30 days when refrigerated. Sterile water has no preservative and must be used within 24 to 48 hours. For sourcing, see where to buy bacteriostatic water for injection.

1. 1.Clean both vial stoppers with alcohol swabs. Let dry for 10 seconds.
2. 2.Draw bacteriostatic water into the syringe. For a 2 mg vial, use 1 mL (gives 2 mg/mL or 2,000 mcg/mL). For a 5 mg vial, use 2.5 mL (gives 2 mg/mL).
3. 3.Insert the needle into the CJC-1295 vial at a slight angle. Let the water flow slowly down the inside wall of the glass. Never spray directly onto the lyophilized powder.
4. 4.Swirl gently in a circular motion. Never shake. Shaking creates foam and denatures the peptide.
5. 5.Wait until fully dissolved. The solution should be clear and colorless. If cloudy, refrigerate for 15 minutes and swirl again.
6. 6.Label the vial with the date and concentration (e.g., "CJC no DAC, 2 mg/mL, reconstituted 03/17").
7. 7.Refrigerate immediately at 2 to 8 degrees Celsius.

Use the reconstitution calculator to determine exact volumes for your vial size and desired concentration. For comprehensive reconstitution guidance, see how to reconstitute peptides.

With a 2 mg vial reconstituted in 1 mL bacteriostatic water (2,000 mcg/mL concentration):

With a 5 mg vial reconstituted in 2.5 mL bacteriostatic water (2,000 mcg/mL concentration):

At the standard no-DAC protocol of 100 mcg before bed, a single 5 mg vial provides 50 doses: nearly two months of daily injections. That makes CJC-1295 one of the most cost-effective GH peptides available. Compare costs with the peptide cost calculator. For storage guidelines, see how to store peptides and how long do reconstituted peptides last.

Timing depends on the variant and your goal.

CJC-1295 with DAC: Timing is flexible. The 5 to 8-day half-life means the injection time barely matters. Most users inject in the morning on their chosen day(s) for consistency. There is no meaningful advantage to fasted versus fed injection with the DAC variant because the GH elevation is sustained over days, not minutes.

CJC-1295 without DAC: Timing matters significantly. The GH pulse peaks within 15 to 30 minutes and clears within 2 hours. For maximum effect:

The before-bed injection is the highest-priority window. If you inject only once daily, this is the one to choose. The natural GH surge during slow-wave sleep is the largest of the day, and GHRH amplifies it substantially.

Subcutaneous injection sites for CJC-1295:

• Abdomen: Most common. Pinch a fold of skin 2 or more inches from the navel. Inject at a 45-degree angle.
• Front of thigh: Middle third of the upper leg. A good alternative for daily rotation.
• Upper arm (back): Viable but harder to self-inject.

For daily injections, rotate between at least three sites to prevent injection site reactions and lipohypertrophy. A simple rotation: abdomen (right), abdomen (left), right thigh, left thigh, repeat. Mark the injection site and date in a notebook or phone note. At the volumes used for no-DAC CJC-1295 (0.05 to 0.15 mL per injection), injection site reactions are rare because the fluid volume is so small.

Water retention is the most frequently reported side effect and is directly proportional to dose and GH elevation. It typically manifests as slightly puffy fingers or ankles. Reducing sodium intake and increasing water consumption helps the body adapt within 2 to 4 weeks. If numbness or tingling in the hands persists beyond 2 weeks, reduce the dose by 50% and reassess. Persistent carpal tunnel symptoms indicate IGF-1 levels may be too high.

Monitor IGF-1 levels to ensure GH elevation stays within the physiological range. Excessive IGF-1 carries long-term risks including potential promotion of existing cancerous cells. This is a theoretical concern from epidemiological data, not a demonstrated side effect of CJC-1295, but it warrants monitoring (Renehan et al., Lancet 2004).

Recommended testing schedule:

• Baseline: Before starting CJC-1295
• 6 weeks: Assess initial response
• 12 weeks: Confirm levels before continuing

Target: IGF-1 in the upper third of the age-adjusted reference range. For most adults under 50, this means 200 to 300 ng/mL. If IGF-1 exceeds 3 standard deviations above the age-adjusted mean, reduce dose or discontinue. For overall peptide safety protocols, see the peptide safety guide.

The standard 8 to 12 weeks on, 4 weeks off protocol balances efficacy with recovery. During the off period, GH levels return to baseline within 1 to 2 weeks (for no-DAC) or 2 to 3 weeks (for DAC). IGF-1 follows with a slight delay, normalizing within 3 to 4 weeks after the last injection.

Do not stack multiple GH secretagogues during the off period as a "bridge." The point of the off period is pituitary recovery. Using MK-677 during the CJC-1295 off period defeats the purpose.

Track your peptide clearance with the peptide half-life tracker.

Three signals indicate the pituitary is fatiguing:

1. 1.Diminishing sleep quality. The sleep improvement from nighttime GH peptides is one of the first benefits to appear and one of the first to fade when desensitization begins.
2. 2.Water retention that no longer resolves. Early-cycle water retention typically subsides within 2 to 4 weeks. If it returns or worsens at month 3, the body is struggling to process continuous GH stimulation.
3. 3.Stable or rising IGF-1 with reduced subjective benefits. If bloodwork shows IGF-1 remains elevated but you no longer feel the recovery and sleep benefits, the receptor response is downregulating despite adequate GH production.

When any of these appear, begin your off period regardless of where you are in the planned cycle. Pushing through desensitization wastes peptide and delays recovery.